US Patent

US10421729 — Microcrystalline diketopiperazine compositions and methods

Formulation · Assigned to Mannkind Corp · Expires 2035-04-01 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for making microcrystalline diketopiperazine particles that can be used for pulmonary delivery of peptides, proteins, or nucleic acids.

USPTO Abstract

Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules.

Drugs covered by this patent

Patent Metadata

Patent number
US10421729
Jurisdiction
US
Classification
Formulation
Expires
2035-04-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Mannkind Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.